Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 100,963,692 | 111,444,313 | 82,047,252 | 104,423,511 | 107,001,067 | 505,879,835 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 100,963,692 | 111,444,313 | 82,047,252 | 104,423,511 | 107,001,067 | 505,879,835 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 54,196,231 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 451,683,604 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 100,963,692 | 111,444,313 | 82,047,252 | 104,423,511 | 107,001,067 | 505,879,835 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,455,907 | 5,237,546 | 7,508,720 | 9,515,640 | 8,590,825 | 34,308,638 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | 0 | 0 | 0 | 0 | 0 |
| 11 | Total support. Add lines 7 through 10 | 540,188,473 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2019 | (b) 2020 | (c) 2021 | (d) 2022 | (e) 2023 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2023 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2023 |
(iii) Distributable Amount for 2023 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2023 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2023 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2023: | ||||
| a From 2018....... | ||||
| b From 2019....... | ||||
| c From 2020....... | ||||
| d From 2021....... | ||||
| e From 2022....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2023 distributable amount | ||||
|
i
Carryover from 2018 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2023 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2023 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2023, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2023. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2024. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2019..... | ||||
| b Excess from 2020..... | ||||
| c Excess from 2021..... | ||||
| d Excess from 2022..... | ||||
| e Excess from 2023..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 23017437 |
| Software Version: | 2023v6.0 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 MISSION STATEMENT | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE'S MISSION IS TO ADVANCE THE BIOMEDICAL SCIENCES BY CULTIVATING THE NEXT GENERATION OF SCIENTIFIC LEADERS, PROVIDING MEANINGFUL OPPORTUNITIES FOR RESEARCHERS OF ALL BACKGROUNDS TO LEARN, INNOVATE, AND MAKE BREAKTHROUGH DISCOVERIES THAT IMPROVE HUMAN HEALTH. |
| Form 990, Part III, Line 4a | Form 990 - Part III, line 4 Program Service Accomplishments Sanford Burnham Prebys is an independent nonprofit medical research organization dedicated to uncovering the origins of disease and launching bold new strategies that lay the foundation for cures. The institute has deep expertise in fundamental biology highlighted by four disease-focused centers, two technology-enabling centers and four cross-cutting themes; stem cells and regenerative medicine; and the Sanford Children's Health Research Center. Cancer Selected published research How a protein component of nuclear pore complexes regulates development of blood cells and may contribute to myeloid disorders. Maximiliano D' Angelo, PhD, et al. Science Advances. June 5, 2024. How tumor stiffness alters immune cell behavior to escape destruction. Kevin Tharp, PhD, and Kelly Kersten, PhD, et al. Nature Cancer. June 3. 2024. Overlooked lipid connected to ancient cellular pathway with links to cancer. Brooke Emerling, PhD, et al. Science Signaling. May 28, 2024. AI tool predicts responses to cancer therapy using information from each cell of the tumor. Sanju Sinha, PhD, et al. Nature Cancer. Apr 18, 2024. What makes a pathogen antibiotic-resistant? Andrei L. Osterman, PhD, et al. npj Antimicrobials and Resistance. Mar 2, 2024. New genome mapping tool may uncover secrets for treating blood cancers. Kristiina Vuori, MD, PhD, et al. Cancers. Jan 18, 2024. The "Eph" system may pave the way for novel cancer therapies. Elena Pasquale, PhD, et al. Nature Reviews Cancer. Nov 27, 2023. "DNA loops" in pediatric brain tumors double relapse risk. Lukas Chavez, PhD, et al. Nature Genetics. Nov 14, 2023. Copycat nutrient leaves pancreatic tumors starving. Cosimo Commisso, PhD, et al. Nature Cancer. Oct 8, 2023. This sugar kills honeybees-it could also help fight cancer. Hudson Freeze, PhD, et al. eLife. July 17, 2023. Cardiovascular and Muscular Diseases Selected published research New genes implicated in deadly heart defect. Rolf Bodmer, PhD, and George Vogler, PhD, et al. eLife. July 17, 2023. Neurologic Diseases Selected published research Tiny brain bubbles carry complete codes. Jerold Chun, MD, PhD, et al. Cell Reports. Apr 23, 2024. Common HIV treatments may aid Alzheimer's disease patients. Jerold Chun, MD, PhD, et al. Pharmaceuticals. Mar 22, 2024. Similarity between vitamin B12 loss and multiple sclerosis revealed. Jerold Chun, MD, et al. Cell Reports. Dec 8, 2023. Inhibiting an enzyme associated with aging could help damaged nerves regrow and restore strength. Yu Xin Wang, PhD, et al. Science Translational Medicine. Oct 11, 2023. Metabolic and Liver Diseases Selected published research A new 3D bioprinted model offers a novel tool to study common liver disease, and perhaps find an effective treatment. David Brenner, MD, et al. American Journal of Pathology. Dec 27, 2023. How liver cells become scarring, and worse. David Brenner, MD, et al. Cellular and Molecular Gastroenterology and Hepatology. Sept 27, 2023. Cross-cutting Themes New roles for autophagy genes in cellular waste management and aging. Malene Hansen, PhD, et al. Nature Aging. Jan 4. 2024. A potential new weapon against a deadly, drug-resistant bacterial pathogen. Andrei Osterman, PhD, et al. Nature. Jan 3, 2024. Study reveals Zika's shape-shifting machinery-and a possible vulnerability. Alexey Terskikh, PhD, et al. PLOS Pathogens. Nov 27, 2023. Selected Awards and Grants Michael Jackson, PhD, and collaborators at Cedars-Sinai have received a four-year, $2.5 million grant from the National Cancer Institute to target the mutant promoter of TERT, which is associated with an increased risk of acute myeloid leukemia. Tim Huang, PhD, was awarded a five-year, $4.3 million grant from the National Institute on Aging to study the potential therapeutic value of SORLA against Alzheimer's disease and related tauopathies. The research is in collaboration with Kevin Yip, PhD. Sanjeev Ranade, PhD, received a three-year, $752,000 award from Additional Ventures to define neural crest regulatory networks and lineages in outflow tract development. Georg Vogler, PhD, was awarded a 3-year, $142,000 grant from the National Aeronautics and Space Administration (NASA) to study the neurological, cardiac and muscular consequences of living in a deep space environment, using the model organism Drosophila melanogaster (fruit fly). Yu Xin Wang, PhD, received a 1-year, $50,000 award from the Department of Health & Human Services (NIH) to study CODEX multiplex immunofluorescence to detect cellular senescence, part of the Cellular Senescence Network initiative. Jerold Chun, MD, PhD, was awarded a 3-year, $660,000 grant from the Larry L. Hillblom Foundation to continue his research into mosaicism and its contribution to age-related neurological disease. Yu Xin Wang, PhD, received a 1-year, $50,000 award from the Department of Health & Human Services (NIH) to study CODEX multiplex immunofluorescence to detect cellular senescence, part of the Cellular Senescence Network initiative David Brenner, MD, received a 5-year, $1.5 million from the NIH and the Department of Health & Human Services to study how collagen fibers and fragments regulate pancreatic cancer metabolism and growth. Nicholas Cosford, PhD, received a 3-year, $500,000 award from Curebound to further pursue the therapeutic potential of ULK1 inhibitor proteins, which have been shown to be a promising biomarker in predicting prognoses and clinical response to cancer treatments. Cosimo Commisso, PhD, received a 1-year, $195,000 award from Curebound to study ion homeostasis as a new drug target for pancreatic cancer treatments. Maximiliano D'Angelo, PhD, received a 2-year, $300,000 Discovery Boost Grant from the American Cancer Society to further his research on how components of nuclear pore complexes (multiprotein channels that act as gatekeepers to the genome) modulate the anti-tumor immune response and might be used as therapeutic targets. |
| Form 990, Part VI, Line 11b Review of form 990 by governing body | PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990: THE 990 IS PREPARED BY THE FINANCE DEPARTMENT. IT IS REVIEWED BY THE INSTITUTE'S TAX ADVISORS, SELECTED MEMBERS OF MANAGEMENT INCLUDING THE CFO AND AUDIT COMMITTEE, AND PROVIDED TO MEMBERS OF THE BOARD PRIOR TO FILING. |
| Form 990, Part VI, Line 12c Conflict of interest policy | DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICT OF INTEREST: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUE HAS A CONFLICT OF INTEREST POLICY THAT REQUIRES ALL TRUSTEES, PRINCIPAL OFFICERS OR MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS TO ANNUALLY CONFIRM THEIR RECEIPT OF THE CONFLICT OF INTEREST POLICY AND DISCLOSE ANY NEW ASSOCIATIONS OR INTEREST THAT MIGHT POTENTIALLY POSE A CONFLICT. THIS IS A WRITTEN CONFIRMATION THAT SHE OR HE READ AND UNDERSTANDS THE CONFLICT OF INTEREST POLICY, WILL ABIDE BY THE CONFLICT OF INTEREST POLICY AND CERTIFIES DISCLOSURE OF ALL INTERESTS OR RELATIONSHIPS THAT MAY POSE CONFLICTS. NEW TRUSTEES RECEIVE TRAINING REGARDING THE INSTITUTE'S CONFLICT OF INTEREST POLICY, WHICH INCLUDES HOW TO IDENTIFY A CONFLICT OF INTEREST AND HOW TO HANDLE POSSIBLE CONFLICTS OF INTEREST WHEN THEY ARISE. THE COMPLIANCE DEPARTMENT REVIEWS EACH OF THE STATEMENTS AND ASSESSES WHETHER AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST EXISTS AND REFERS THE MATTER TO THE BOARD TO WHETHER THE INDIVIDUAL SHOULD BE PROHIBITED FROM CONSIDERATION OF RELATED ITEMS. ANY TRUSTEE, PRINCIPAL OFFICER OR MEMBER OF A COMMITTEE WITH BOARD DELEGATED POWERS WITH A CONFLICT IN A MATTER REQUIRING ACTION BY THE BOARD ARE PROHIBITED FROM PARTICPATING IN THE BOARD'S DELIBERATIONS AND/OR VOTING ON THE PARTICULAR TRANSACTION OR MATTER IN WHICH HE OR SHE HAS AN INTEREST; AND OTHERWISE REFRAIN FROM EXERTING ANY INFLUENCE TO AFFECT A DECISION. HOWEVER, OTHER MEASURES MAY BE REQUIRED, DEPENDING ON THE NATURE OF AND THE ABILITY TO REASONABLY MANAGE A CONFLICT. |
| Form 990, Part VI, Line 15a Process to establish compensation of top management official | COMPENSATION FOR THE CEO AND PRESIDENT, CHIEF FINANCIAL OFFICER, AND OTHER KEY EMPLOYEES IS ESTABLISHED ACCORDING TO INSTITUTE POLICIES THAT ARE DESIGNED TO MEET THE IRS STANDARD FOR "REBUTTABLE PRESUMPTION OF REASONABLENESS". THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES, CONSISTING OF AT LEAST THREE INDEPENDENT TRUSTEES, REVIEWS COMPARABILITY DATA AT LEAST EVERY TWO YEARS PROVIDED BY AN INDEPENDENT EXTERNAL CONSULTANT/RESOURCE THAT INCORPORATES AND EVALUATES INSTITUTE DATA AND THAT OF COMPARABLE ORGANIZATIONS AND MARKETS FROM WHICH THE INSTITUTE DRAWS ITS EXECUTIVE TALENT. UTILIZING THIS INFORMATION, THE COMPENSATION COMMITTEE MAKES A DETERMINATION WHETHER THE PROPOSED COMPENSATION IS REASONABLE. THE COMPENSATION COMMITTEE HAS BEEN DELEGATED AUTHORITY BY THE BOARD OF TRUSTEES TO REVIEW AND APPROVE COMPENSATION OF ALL POSITIONS EXCEPT FOR THE CEO. THE CEO'S COMPENSATION PACKAGE IS REVIEWED AND APPROVED INITIALLY BY THE COMPENSATION COMMITTEE AND THEN GOES TO THE EXECUTIVE COMMITTEE FOR FINAL APPROVAL. THE COMPENSATION COMMITTEE CONTEMPORANEOUSLY AND ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION AND RECOMMENDATION TO THE EXECUTIVE COMMITTEE. IF APPROVED BY THE EXECUTIVE COMMITTEE, THE CEO COMPENSATION PACKAGE IS THEN IMPLEMENTED AND SUCH DOCUMENTATION IS KEPT IN THE WRITTEN AND ELECTRONIC RECORDS OF THE BOARD OF TRUSTEES. THE PROCESS WAS LAST COMPLETED ON JUNE 27, 2023. THE NEXT REVIEW WILL BE COMPLETED JUNE 2025. |
| Form 990, Part VI, Line 15b Process to establish compensation of other employees | SEE ABOVE |
| Form 990, Part VI, Line 19 Required documents available to the public | PROCESS FOR MAKING DOCUMENTS AVAILABLE TO THE PUBLIC: DOCUMENTS ARE AVAILABLE UPON REQUEST AND THE INSTITUTE'S TAX FORM 990 IS AVAILABLE ON CHARITY NAVIGATOR AND GUIDESTAR. |
| Form 990, Part VIII, Line 11d Other Miscellaneous Revenue | ALL OTHER REVENUE - Total Revenue: 6000, Related or Exempt Function Revenue: 6000, Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: ; |
| Schedule F, Part I, Line 3 Program Service Activities | Sanford Burnham Prebys Medical Discovery Institute does not maintain ongoing operations in foreign jurisdictions. However, the Institute's scientists do travel to various scientific conferences in other countries to share the Institute's scientific discoveries, as well as, to learn from other scientists across the world. |
| Schedule F, Part I, Line 3(e) Type of Service | Specific Program Service Activity in all regions is employees attending and/or speaking at scientific conferences and collaborations. |
| Schedule F, Part I, Line 3(f) Accounting Method | The accrual method of accounting was used to determine the amounts in Part I, line 3, column F. |
| Software ID: | 23017437 |
| Software Version: | 2023v6.0 |